Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
Adalimumab save search
Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®
Published: 2024-02-24 (Crawled : 04:20) - globenewswire.com
KMDA | $5.075 -0.1% -0.1% 6.5K
|
Health Technology
| Email alert
Add to watchlist
ALVO | $12.9 0.78% 0.78% 90K
|
n/a
| Email alert
Add to watchlist
TEVJF | $12.37 -24.22% 380
|
Health Technology
| Email alert
Add to watchlist
simlandi first biosimilar approval teva
Alvotech Provides U.S. Regulatory Update on AVT02, a High-Concentration Interchangeable Biosimilar Candidate to Humira® (adalimumab)
Published: 2023-09-20 (Crawled : 09:00) - globenewswire.com
ALVO | $12.9 0.78% 0.78% 90K
|
n/a
|
| O: 2.12%
H: 0.0%
C: -2.5%
KMDA | $5.075 -0.1% -0.1% 6.5K
|
Health Technology
|
| O: -0.95%
H: 1.92%
C: 1.15%
avt02 humira candidate biosimilar update
Alvotech and Bioventure Announce Approval of AVT02 (adalimumab) in Egypt
Published: 2023-08-29 (Crawled : 09:00) - globenewswire.com
ALVO | $12.9 0.78% 0.78% 90K
|
n/a
|
| O: -0.93%
H: 3.75%
C: 2.39%
KMDA | $5.075 -0.1% -0.1% 6.5K
|
Health Technology
|
| O: 0.55%
H: 2.24%
C: 0.92%
avt02 approval egypt
Sandoz to launch Hyrimoz® (adalimumab-adaz) high-concentration formulation, marking Sandoz entrance into US immunology space
Published: 2023-07-01 (Crawled : 04:20) - globenewswire.com
NVSEF | $93.6375 6.88% 82K
|
Health Technology
| Email alert
Add to watchlist
NVS | $92.57 -0.55% 0.0% 910K
|
Health Technology
| Email alert
Add to watchlist
hyrimoz space immunology
Rani Therapeutics and Celltrion Expand Partnership to Include Adalimumab Biosimilar for RT-105
Published: 2023-06-05 (Crawled : 12:00) - globenewswire.com
RANI | $6.11 -22.17% -28.48% 580K
|
|
| O: 0.89%
H: 4.87%
C: 2.43%
rt-105 partnership biosimilar therapeutics
Coherus Announces Industry-Wide Lowest List Price for Adalimumab Biosimilar YUSIMRY™ (adalimumab-aqvh) Launching in July 2023List price of $995 per carton for two 40 mg/0.8 mL autoinjectors
Published: 2023-06-01 (Crawled : 18:00) - biospace.com/
CHRS | $1.99 -7.44% -8.04% 1.9M
|
Health Technology
|
| O: 1.96%
H: 1.68%
C: -2.88%
biosimilar
Coherus Announces Industry-Wide Lowest List Price for Adalimumab Biosimilar YUSIMRY™ (adalimumab-aqvh) Launching in July 2023
Published: 2023-06-01 (Crawled : 12:00) - globenewswire.com
CHRS | $1.99 -7.44% -8.04% 1.9M
|
Health Technology
|
| O: 1.96%
H: 1.68%
C: -2.88%
biosimilar
Sandoz receives US FDA approval for biosimilar Hyrimoz® (adalimumab-adaz) high-concentration formulation
Published: 2023-03-21 (Crawled : 15:00) - globenewswire.com
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: 1.89%
H: 0.0%
C: -1.15%
NVS | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: 0.25%
H: 0.19%
C: 0.04%
hyrimoz fda biosimilar approval
AMJEVITA™ (ADALIMUMAB-ATTO), FIRST BIOSIMILAR TO HUMIRA®, NOW AVAILABLE IN THE UNITED STATES
Published: 2023-01-31 (Crawled : 14:00) - biospace.com/
BGNE | $131.94 0.06% 0.06% 130K
|
Health Technology
|
| O: -0.74%
H: 1.16%
C: 0.69%
AMGN | $262.77 -0.49% -0.49% 2M
|
Health Technology
|
| O: 0.9%
H: 0.0%
C: -0.58%
humira biosimilar
Sandoz receives positive CHMP opinion for citrate-free high concentration formulation of adalimumab biosimilar
Published: 2023-01-30 (Crawled : 07:00) - globenewswire.com
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: 0.0%
NVS | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: 0.65%
H: 0.37%
C: -0.48%
biosimilar chmp positive
Alvotech and Bioventure Announce Approval of AVT02 (adalimumab) as Simlandi in Saudi Arabia
Published: 2023-01-24 (Crawled : 10:00) - globenewswire.com
ALVO | $12.9 0.78% 0.78% 90K
|
n/a
|
| O: -1.34%
H: 2.21%
C: 0.85%
KMDA | $5.075 -0.1% -0.1% 6.5K
|
Health Technology
|
| O: -1.04%
H: 0.0%
C: -2.73%
avt02 approval
Alvotech and STADA Broaden Access to Hukyndra® adalimumab biosimilar in Europe
Published: 2022-12-07 (Crawled : 10:00) - globenewswire.com
ALVO | $12.9 0.78% 0.78% 90K
|
n/a
|
| O: 0.44%
H: 9.12%
C: 8.25%
KMDA | $5.075 -0.1% -0.1% 6.5K
|
Health Technology
|
| O: -0.87%
H: 0.88%
C: 0.66%
hukyndra europe biosimilar
Adalimumab Found To Be A Likely Cost-Effective Treatment for Early-Stage Dupuytren’s Disease
Published: 2022-11-15 (Crawled : 18:00) - biospace.com/
ATNF | $1.91 0.0% 91K
|
|
| O: 1.78%
H: 19.08%
C: 10.06%
treatment disease
CORRECTION: Adalimumab Found To Be A Likely Cost-Effective Treatment for Early-Stage Dupuytren’s Disease
Published: 2022-11-15 (Crawled : 18:00) - globenewswire.com
ATNF | $1.91 0.0% 91K
|
|
| O: 1.78%
H: 19.08%
C: 10.06%
treatment disease
Alvotech and STADA Increase Access to Adalimumab for Patients in Switzerland with the Launch of Hukyndra®
Published: 2022-09-22 (Crawled : 12:20) - globenewswire.com
ALVO | $12.9 0.78% 0.78% 90K
|
n/a
|
| O: -5.35%
H: 1.38%
C: -10.07%
KMDA | $5.075 -0.1% -0.1% 6.5K
|
Health Technology
|
| O: -0.67%
H: 1.57%
C: 0.0%
hukyndra switzerland
Sandoz Application for proposed biosimilar adalimumab’s high concentration formulation accepted by EMA
Published: 2022-06-17 (Crawled : 06:00) - globenewswire.com
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: 0.74%
H: 0.52%
C: -3.23%
NVS | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: 0.07%
H: 0.0%
C: 0.0%
biosimilar ema application
STADA and Alvotech broaden European patients’ options by launching Hukyndra® high-concentration, citrate-free adalimumab
Published: 2022-06-09 (Crawled : 12:00) - biospace.com/
KMDA | $5.075 -0.1% -0.1% 6.5K
|
Health Technology
|
| O: -1.62%
H: 0.0%
C: -5.54%
hukyndra
Celltrion Healthcare announces the availability of Yuflyma a high-concentration, low-volume, citrate-free, and latex-free Humira (adalimumab) biosimilar in Canada
Published: 2022-04-11 (Crawled : 16:00) - biospace.com/
ABBV | News | $164.66 0.25% -0.15% 4.5M
|
Health Technology
|
| O: -0.03%
H: 0.08%
C: -2.9%
humira biosimilar canada
AbbVie Resolves HUMIRA® (adalimumab) U.S. Litigation with Alvotech
Published: 2022-03-08 (Crawled : 22:00) - prnewswire.com
ABBV | News | $164.66 0.25% -0.15% 4.5M
|
Health Technology
|
| O: 0.65%
H: 0.0%
C: 0.0%
humira
Celltrion Healthcare announces Canadian approval of Yuflyma, a high-concentration, low-volume, citrate-free, and latex-free Humira (adalimumab) biosimilar
Published: 2022-01-31 (Crawled : 15:30) - biospace.com/
ABBV | News | $164.66 0.25% -0.15% 4.5M
|
Health Technology
|
| O: -0.67%
H: 0.0%
C: 0.0%
health thc approval cel humira biosimilar
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.